Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“NLRP3 Inhibition in Atherosclerosis: Early Clinical Signal Beyond Lipids
Targeting residual inflammatory risk has become a central challenge in contemporary cardiovascular prevention, particularly in patients who achieve optimal LDL-C control yet remain at elevated risk.
Within this framework, the NLRP3 inflammasome has emerged as a pivotal upstream regulator of vascular inflammation, orchestrating the IL-1B-IL-6-CRP signaling cascade that drives plaque progression, instability, and eventual clinical events.
Early clinical evidence with the oral NLRP3 inhibitor VTX3232 provides a compelling proof-of-concept for this therapeutic strategy.
In a randomized, double-blind phase 2a trial involving individuals with obesity and heightened cardiometabolic risk, treatment with VTX3232 led to profound reductions in inflammatory biomarkers, including up to a ~78% decrease in hsCRP and significant suppression of IL-6 levels.
Notably, these anti-inflammatory effects occurred independently of weight loss, underscoring a mechanism distinct from metabolic modulation.
When combined with semaglutide, VTX3232 demonstrated additive reductions in hsCRP, IL-6, lipoprotein(a), and fibrinogen, suggesting a complementary role alongside established cardiometabolic therapies. These findings reinforce the concept of targeting inflammation as an orthogonal axis of risk reduction.
However, current evidence remains limited to biomarker modulation, with no demonstrated impact on hard cardiovascular outcomes such as myocardial infarction, stroke, or cardiovascular mortality.
While mechanistically robust and clinically promising, the ultimate role of NLRP3 inhibition in atherosclerosis will depend on large-scale, event-driven trials.
Reference:
- Ventyx Biosciences. Phase 2a Study of VTX3232 in Cardiometabolic Risk (ACC 2026 Presentation);
- Molecular Metabolism (2025);
- Healio Cardiology News (2026).”
More posts featuring Ney Carter Borges on Hemostasis Today.
-
May 31, 2026, 07:00Ceri Roberts: How to Reduce Your Risk of a Blood Clot
-
May 31, 2026, 05:28Nikolaos Androulakis: Inflammatory Burden and Antiphospholipid Antibodies in Lupus Anticoagulant Testing
-
May 31, 2026, 05:28Alysha Arif: Understanding a Complex Case of Postpartum Seizures
-
May 31, 2026, 05:27Chiara Novelli: Are We Validating Laboratory Algorithms as Rigorously as We Validate Laboratory Tests?
-
May 31, 2026, 02:42Katja van den Hurk: Optimizing Iron Management in Blood Donors
-
May 31, 2026, 02:36The New JPAC Website Has Been Live for Nearly a Week – SHOT
-
May 31, 2026, 02:33Jecko Thachil: Is It Possible to Use Machine Learning for Differentiating Inherited Thrombocytopenia from Other Causes?
-
May 30, 2026, 18:12Khokon Miah Akanda: FDA Approves a First-in-Class Hypertension Drug
-
May 30, 2026, 18:11Alessandro Perrella: It is Not Only about “How High the CRP is”, but “in Which Patient” We are Measuring That Value